Clinical Trial Update: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating whether adding ganitumab to standard chemotherapy improves outcomes in newly diagnosed metastatic Ewing sarcoma; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Peripheral Primitive Neuroectodermal Tumor of Bone
• Peripheral Primitive Neuroectodermal Tumor of Soft Tissues

Drugs mentioned

• Ganitumab (ganitumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-07-01